Abivax oral anti-inflammatory drugs to treat ulcerative colitis IIa trial was successful.

Abivax is a clinical biotech company dedicated to developing innovative therapies that stimulate the body's natural immune mechanisms to treat inflammatory diseases, viral diseases and cancers.
recently, the company released data on abX464 treatment for ulcerative colitis (UC) phase IIa.
the study group, previously insatiable and/or difficult to treat at least one existing treatment.
2-year maintenance treatment showed that 69% of patients received clinical remission and 94% benefited from clinical response.
data confirm that ABX464 has good safety and efficacy in the second year of maintenance therapy, which has been observed during the induction period of the study and in the first year of maintenance therapy.
new findings strengthen ABX464's potential as a well-to-do, effective, daily oral therapy for moderate to severe UC patients.
of the 32 patients who were included in the active drug group or the placebo group during the initial induction period, 22 were included in the IIa period maintenance study and received a daily 50 mg dose of ABX464 open label therapy.
, 19 patients completed the first year (52 weeks) abx464 maintenance therapy, and 16 of the 19 patients completed the second year ABX464 maintenance therapy.
the results of all endoscopes are read out centrally by independent examiners.
data show that 11 (69%) of the 16 patients who completed maintenance therapy in the second year were in clinical remission and 15 (94%) benefited from clinical response.
7 cases (44%) were in endoscopic remission (including the complete disappearance of colon/rectal lesions.
calprotectin, a key biomarker of UC disease activity, was normalized during the first year of treatment and remained at 31.6 μg/g during the second year (normal levels were less than 50?g/g).
, ABX464 was safe, well-to-bear, and no serious adverse reactions were reported.
the second year of ABX464 treatment, no patient stopped taking the drug prematurely due to adverse events.
UC is an inflammatory bowel disease that greatly affects the quality of life of patients and requires expensive and cumbersome treatment.
The results of the two-year duration of the above-mentioned IIa study confirm that the innovative mechanism of ABX464 will provide a promising new approach to moderate to severe UC patients receiving unresponsive or discontinued treatments from existing therapies, including biologics, providing an easy, daily oral, and long-term effective treatment option.
ABX464 Chemical Structure (Photo: aidsinfo.nih.gov) ABX464 is a small molecular drug screened from Abivax's compound library, which includes more than 2,200 small molecules that can be clipped with adjustable RNA.
effects of THE RNA shear regulation of ABX464 constitute a powerful anti-inflammatory and antiviral effect and have the ability to reduce HIV reservoir.
, ABX464 is currently being developed for a variety of inflammatory diseases (including UC, Crohn's disease, rheumatoid arthritis) and a variety of viral diseases (COVID-19, HIV).
anti-inflammatory effect of ABX464 is triggered by the molecule binding to the Target Hat Binding Complex (CBC), which is located at the 5' end of each cell of non-coding RNA molecules.
this combination can lead to a long, non-coded RNA shearing that induces overexposing of miR-124, a single tiny RNA (miRNA) product.
miR-124 then initiates a cascading reaction that produces a powerful anti-inflammatory effect.
clinical development, IIb phase induction and maintenance studies for moderate to severe UC patients treated by ABX464 are being conducted in Europe, Canada and the United States, and so far 69% (159/232) of patients have been randomized into induction studies.
the study is expected to be completed by the end of this year, with the first top-line results to be announced in the second quarter of 2021.
of the 85 patients who completed the induction period, 84 entered the maintenance period and are currently receiving a daily oral 50 mg dose of ABX464, which has shown good safety consistent with previous studies.
addition, ABX464 treatment rheumatoid arthritis IIa phase of the study of patients in the group is progressing smoothly, is expected to be completed by the end of the year.
same time, the PHASE IIb/III trial of ABX464 for patients with new coronavirus pneumonia (COVID-19) has been approved in all participating European countries and Brazil, and patient recruitment is under way and is expected to be completed in the fourth quarter.
, abivax is planning to push ABX464 to the crohn's disease-critical Phase IIb/III trial, which is expected to begin recruiting patients in 2021, according to key leaders.
source: ABIVAX: Abivax Reports Long-lasting Two-year Efficacy and Safety Safety Data FROM ABX464 Ulcerative Colitis Phase 2a Maintenance Study.